Despite billions of investments in research, Boehringer Ingelheim remains independent. Head of the company Deshpande wants to remain independent of external capital.
Despite billions of investments in research, Boehringer Ingelheim remains independent. Head of the company Deshpande wants to remain independent of external capital.
The pharmaceutical company Boehringer Ingelheim is one of the world leaders. CEO Shashank Deshpande explains why the family company still does not want to be listed on the stock market and what the placement of the family on the richest list means for its work.